Affiliation:
1. Blokhin National Medical Research Center of Oncology
2. Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University
Abstract
Ramucirumab is a human anti-vascular endothelial growth factor receptor 2(VEGFR-2)monoclonal antibodythat acts on vascular endothelial cells to inhibit angiogenesis. Ramucirumab in monotherapy or in combination with paclitaxel or FOLFIRI has proven to prolong overall survival in patients with pretreated metastatic gastric/gastrooesophageal junction adenocarcinoma. In clinical practice combination with ramucirumab showed promising efficacy with median overall survival in 9,6 months and manageable toxicities. Most common specific adverse events in ramucirumab were impaired wound healing, hypertension, bleeding and perforation. In several article describe dysphonia induced by anti-angiogenic compounds.Herein, we report on a case a high activity ramucirumab in combination with FOLFIRI. This report aims to present a long-term survivor of recurrent gastric cancer and describe dysphonia induced by ramucirumab.
Reference28 articles.
1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
2. Wagner A.D., Syn N.L., Moehler M., Grothe W., Yong W.P., Tai B.C. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Dyst Rev. 2017;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4.
3. Kitadai Y. Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer. Cancer Microenviron. 2010;3(1):109–116. doi: 10.1007/s12307-009-0032-9.
4. Park D.J., Seo A.N., Yoon C., Ku G.Y., Coit D.G., Strong V.E. et al. Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Ann Surg Oncol. 2015;22(3 Suppl.):S1508–S1515. doi: 10.1245/s10434-015-4790-y.
5. Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M. et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858–863. doi: 10.1002/(SICI)10970142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A.